BioSpace News Archive

Abivax announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

Under the terms of the agreement, vTv Therapeutics will run a Phase 2 Multi-Regional Clinical Trial (MRCT) including sites in the US and other regions in the Pacific Rim.

Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures.

BioLineRx announced today initiation of the Phase 3 GENESIS clinical trial, in which BL-8040 will be compared to placebo, on top of G-CSF, for the mobilization of HSCs used for autologous transplantation in multiple myeloma patients.

The CRL indicates that the FDA is unable to approve the application in its present form and requests additional substantiating evidence to demonstrate efficacy of IVT sirolimus in the treatment of noninfectious uveitis of the posterior segment.

Anatomage aims to transform this process with the introduction of Anatomage Cloud.

New investors Lundbeckfonden Ventures and Arix Bioscience plc led the round, with all current investors also participating.

This round was led by Yonghua Capital, with participation from new investors Bristol-Myers Squibb and Norma Investments, representing businessman Roman Abramovich.

Critical Outcome Technologies today announced that its President & Chief Executive Officer, Alison Silva, presented a business and scientific update summarizing recent achievements, upcoming milestones and 2018 objectives at the Company’s Annual General and Special Meeting of Shareholders (“AGM”) held on Wednesday, December 20, 2017.

This agreement draws substantial investment into the sector including the development of a trail-blazing digital pathology program leveraging AI.